Company Overview
Snapshot
Founded in January 2018 by Daniella Gilboa and Prof. Daniel Seidman, AIVF operates with 11–50 employees. The company has raised $25 million across one funding round from 3 investors, with Insight Partners as a lead investor. In October 2022, AIVF acquired ART Compass to enhance its offerings and expand its presence in the US market.
Business overview
AIVF develops advanced AI solutions to optimize In Vitro Fertilization (IVF) treatments, aiming to improve outcomes for patients, clinics, and labs. Its core product, EMA by AIVF, is an AI-powered platform that digitizes and automates IVF clinic operations, connecting care teams, providing AI-based embryo evaluation, streamlining communications, and offering analytics tools. The company serves the healthcare and life sciences sectors, specifically targeting fertility clinics and patients undergoing IVF treatments.
Strategic signal
In September 2023, AIVF expanded its international footprint by launching the first AI-powered IVF operating system in Brazil at the Perfetto Clinic. This strategic expansion into a growing market for assisted reproductive technologies demonstrates AIVF's commitment to global accessibility and positions the company to capture significant market share by addressing increasing demand for advanced fertility solutions.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent partnership for AIVF?
- In May 2023, AIVF partnered with Genea Biomedx to integrate its AI platform with Genea Biomedx's time-lapse incubator. This collaboration aims to enhance the efficiency and success rates of IVF clinics globally by providing personalized and optimized IVF care.
- What recognition did AIVF receive in 2023?
- In June 2023, AIVF was awarded as a 2023 Technology Pioneer by the World Economic Forum. This recognition highlights AIVF's innovative AI-based solutions for IVF clinics and its potential to address industry and societal issues in healthcare.
- What was AIVF's most recent acquisition?
- In October 2022, AIVF acquired ART Compass, an application for managing IVF laboratories. This acquisition expanded AIVF's offerings and aimed to drive the digital transformation of fertility care, particularly strengthening its presence in the US market.
- When did AIVF secure its Series A funding round?
- In June 2022, AIVF raised $25 million in a Series A funding round, led by Insight Partners. This funding was aimed at supporting the company's mission to help more people become parents through AI-assisted IVF technology.
- What was a key regulatory approval for AIVF's platform?
- In April 2021, AIVF received the European CE Mark for its AI-based digital embryology management platform, EMA. This approval was a significant step towards improving the success rates of IVF treatment by combining AI, computer vision, and big data.